XOMAXOMA Corp

Nasdaq xoma.com


$ 27.34 $ -0.36 (-1.3 %)    

Wednesday, 11-Sep-2024 10:45:02 EDT
QQQ $ 453.86 $ -2.33 (-0.51 %)
DIA $ 402.36 $ -2.93 (-0.72 %)
SPY $ 542.06 $ -4.81 (-0.88 %)
TLT $ 100.94 $ 0.24 (0.24 %)
GLD $ 232.10 $ 0.49 (0.21 %)
$ 27.7
$ 27.15
$ 27.45 x 100
$ 30.05 x 100
$ 27.15 - $ 27.34
$ 13.48 - $ 30.36
28,771
na
324.21M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-08-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-08-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-10-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-06-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-06-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-03-2016 06-30-2016 10-Q
34 05-04-2016 03-31-2016 10-Q
35 03-09-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 03-11-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-xoma-royalty-raises-price-target-to-117

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:XOMA) with a Buy and raises the price target...

 fda-convenes-expert-panel-meeting-for-zevra-therapeutics-arimoclomol-analyst-optimistic-about-approval-despite-small-patient-base

FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick diseas...

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

 xoma-q1-2024-gaap-eps-086-misses-081-estimate

XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.1...

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...

 leerink-partners-initiates-coverage-on-xoma-with-outperform-rating-announces-price-target-of-40

Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:XOMA) with a Outperform rating and announces Price ...

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles

As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered ...

 hc-wainwright--co-maintains-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

 recap-xoma-q4-earnings
Recap: XOMA Q4 Earnings
03/08/2024 12:40:05

 xoma-fy-gaap-eps-404-may-not-be-comparable-to-205-estimate-sales-476m-miss-650m-estimate

XOMA (NASDAQ:XOMA) reported quarterly losses of $(4.04) per share which missed the analyst consensus estimate of $(2.05) by 97....

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION